OverviewSuggest Edit

AlloVir (formerly ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. It focuses on the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients.

TypePublic
Founded2013
HQHouston, TX, US
Websiteallovir.com

Latest Updates

Employees (est.) (Jul 2020)21
Revenue (FY, 2019)$165 K(-85%)
Share Price (Jan 2021)$42.7 (-5%)
Cybersecurity ratingAMore

Key People/Management at AlloVir

Jeroen van Beek

Jeroen van Beek

Chief Commercial Officer

AlloVir Office Locations

AlloVir has offices in Houston, Cambridge, Waltham and Milano
Houston, TX, US (HQ)
2925 Richmond Ave
Cambridge, MA, US
139 Main St #500
Waltham, MA, US
200 Smith St #301
Milano, IT
Via Melchiorre Gioia, 8
Show all (4)

AlloVir Financials and Metrics

AlloVir Revenue

AlloVir's revenue was reported to be $165 k in FY, 2019 which is a 85.5% decrease from the previous period.
USD

Net income (Q2, 2020)

(11.6m)

EBIT (Q2, 2020)

(12.2m)

Market capitalization (22-Jan-2021)

2.6b

Closing stock price (22-Jan-2021)

42.7

Cash (30-Jun-2020)

78.3m

EV

2.6b
AlloVir's current market capitalization is $2.6 b.
Annual
USDFY, 2018FY, 2019

Revenue

1.1m165.0k

Revenue growth, %

(85%)

General and administrative expense

3.0m10.6m

R&D expense

1.7m16.2m
Quarterly
USDQ1, 2019Q1, 2020Q2, 2020

Revenue

165.0k

General and administrative expense

1.8m3.0m3.3m

R&D expense

1.2m6.8m8.9m

Operating expense total

2.9m9.8m12.2m
Annual
USDFY, 2018FY, 2019

Cash

22.2m61.1m

Prepaid Expenses

51.0k676.0k

Current Assets

25.3m127.3m

PP&E

350.0k
Quarterly
USDQ1, 2020Q2, 2020

Cash

64.4m78.3m

Prepaid Expenses

960.0k2.4m

Current Assets

117.4m107.3m

PP&E

332.0k313.0k
Annual
USDFY, 2018FY, 2019

Net Income

2.4m(23.8m)

Depreciation and Amortization

19.0k

Accounts Payable

601.0k4.9m

Cash From Operating Activities

1.9m(20.2m)
Quarterly
USDQ1, 2019Q2, 2019Q1, 2020Q2, 2020

Net Income

(2.5m)(7.8m)(9.3m)(21.0m)

Depreciation and Amortization

18.0k37.0k

Accounts Payable

836.0k2.0m(1.5m)(271.0k)

Cash From Operating Activities

(2.0m)(4.9m)(10.5m)(21.7m)
USDFY, 2018

Financial Leverage

-0.8 x
Show all financial metrics

AlloVir Operating Metrics

Jul, 2020

Patents (Foreign)

30

Patents (US)

2

Patents Pending

19

Product Candidates

5
Show all operating metrics

AlloVir Acquisitions / Subsidiaries

Company NameDateDeal Size
AlloVir International Designated Activity Company
AlloVir Italia S.R.L.
AlloVir Securities Corporation

AlloVir Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

AlloVir Online and Social Media Presence

Embed Graph

AlloVir News and Updates

AlloVir Reports Third Quarter 2020 Financial Results

- Completed initial public offering raising $317.7M in gross proceeds

AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support its pipeline of allogeneic, off-the-shelf virus-specific T cell therapies during the 62nd Americ…

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients

- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients

AlloVir Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020.

AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020 at 5:00 p.m. ET.

AlloVir prices upsized IPO at $17, to be valued at over $1 billion

AlloVir Inc. said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share. The company sold 16.25 million shares to raise $276.25 million, up from previous expectations to sell 14.75 million shares. With 61.17 million shares…
Show more

AlloVir Blogs

AlloVir Appoints Ugo Capolino Perlingieri Head of Europe and Middle East Operations

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that Ugo Capolino Perlingieri has been appointed to the newly created position of General Manager of Europe and Middle East operations. In this role, he will be responsible for implementing clinical and commercial progr…

European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced it has been granted Orphan Drug Designation from the European Medicines Agency (EMA) for Viralym-M (ALVR105) as a potential treatment of viral diseases and infections in patients undergoing hematopoietic stem…

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, th…

Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

Research published in the journal BLOOD ADVANCES established the feasibility of using a small bank of third-party cell lines generated from carefully chosen donors to provide virus-specific T-cell therapy to a large number of patients. The data show coverage of more than 95 percent of patients w…

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation

AlloVir, a late-clinical stage allogeneic T-cell therapy company, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for Viralym-M (ALVR105), its lead allogeneic, off-the-shelf, multi-virus specific T-ce…

AlloVir Frequently Asked Questions

  • When was AlloVir founded?

    AlloVir was founded in 2013.

  • Who are AlloVir key executives?

    AlloVir's key executives are Jeroen van Beek.

  • How many employees does AlloVir have?

    AlloVir has 21 employees.

  • What is AlloVir revenue?

    Latest AlloVir annual revenue is $165 k.

  • What is AlloVir revenue per employee?

    Latest AlloVir revenue per employee is $7.9 k.

  • Who are AlloVir competitors?

    Competitors of AlloVir include Corbin Therapeutics, NorInvent and Glycostem.

  • Where is AlloVir headquarters?

    AlloVir headquarters is located at 2925 Richmond Ave, Houston.

  • Where are AlloVir offices?

    AlloVir has offices in Houston, Cambridge, Waltham and Milano.

  • How many offices does AlloVir have?

    AlloVir has 4 offices.